A5031933529- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Metastasis and carcinoma case studies
- Colorectal Cancer Screening and Detection
- Sodium Intake and Health
- Soft tissue tumor case studies
- Colorectal Cancer Surgical Treatments
- Frailty in Older Adults
- Hormonal Regulation and Hypertension
- Neuroblastoma Research and Treatments
- Neutropenia and Cancer Infections
- Electrolyte and hormonal disorders
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Occupational and environmental lung diseases
Ankara University
1995-2024
Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear.
Aim: Identification of patient with increased risk cardiotoxicity would allow not only prevention and early diagnosis chemotherapy related but also administration optimal dose duration chemotherapy. Materials methods: Fiftytwo women HER2+ breast cancer treated trastuzumab were included in this study. Patients prospectively followed routine cardiac evaluation. Before after blood samples for NT-proBNP taken. Results: The median age was 48.5 year (range: 26–74). Hypertension obesity two most...
Twenty-one consecutive patients with refractory or relapsed non-Hodgkin's lymphomas were treated a novel combination chemotherapy (MINE-BOP), comprising myelosuppressive (ifosfamide, mitoxantrone, etoposide) and non-myelosupressive (bleomycin, vincristine prednisone) drugs. Median age of the was 42 years all had intermediate high-grade lymphoma. Fifteen disease. All previously been one two regimens, containing anthracyclines. In cases duration between last MINE-BOP regimen shorter than 12...
Based on the promising results of EAP (etoposide, doxorubicin, and cisplatin) combination, a phase II study modified combination was performed in patients with advanced gastric cancer to evaluate response, toxicity, survival.Fifty-two consecutive measurable or evaluable cancer, who had no prior therapy except surgery, were treated every 28 days etoposide 120 mg/m2/day, doxorubicin 25 cisplatin 40 mg/m2/day 1 8, intravenously. Forty-seven for response toxicity.Overall rate 40.5% (95% CI =...